@article{3141760,
    title = "BCL-2, p53 and HLA-DR antigen expression in surgically treated parotid
cancer patients",
    author = "Genetzakis, Michael and Gomatos, Ilias P. and Georgiou, Anastasia N. and and Giotakis, John and Manolopoulos, Leonidas and Papadimitriou, and Isonstantina and Chra, Helen and Leandros, Emmanuel and Tsigris, and Christos and Ferekidis, Eleutherios A.",
    journal = "European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS)",
    year = "2009",
    volume = "266",
    number = "3",
    pages = "417-424",
    publisher = "Springer-Verlag",
    issn = "0937-4477, 1434-4726",
    doi = "10.1007/s00405-008-0754-1",
    keywords = "Bcl-2; HLA-DR; p53; Parotid cancer; Prognosis",
    abstract = "Our objective was to investigate the prognostic significance of bcl-2
protein, p53 protein and HLA-DR antigen expression in a group of
surgically treated parotid cancer patients. We studied bcl-2, p53 and
HLA-DR immunohistochemical expression in paraffin-embedded surgically
removed tissue specimens derived from 26 patients with parotid cancer
and 9 patients with Warthin parotid tumors operated between 2000 and
2006 at the Hippokration Hospital of Athens. The staining results were
correlated with the patients’ clinicopathological characteristics and
clinical outcome. Bcl-2 expression was associated with a significantly
decreased survival in patients with advanced tumor stage (P = 0.04),
high grade lesions (P = 0.02), or cervical node involvement (P = 0.03).
Radiotherapy was associated with a significantly improved
recurrence-free survival among patients with negative tumor staining for
either bcl-2, or both HLA-DR and bcl-2 [HLA-DR(-)/Bcl-2(-)] (P = 0.04
for both comparisons). Classical clinicopathologic factors failed to
show prognostic value both in the univariate and the multivariate
analyses performed. Our results suggest that bcl-2 can be used to
identify locally advanced or histologically aggressive tumors with a
lower survival probability following the application of standard
treatment modalities. Furthermore, bcl-2(+) patients should be
considered for more aggressive adjuvant treatment protocols, since
conventional radiotherapy often fails to decrease relapse rates in this
setting of patients."
}